PYC Therapeutics (ASX:PYC) Tariff Resilience Score: 6/10 (As of Jul. 01, 2026)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
36 GF Score
Price A$1.68
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Tariff Resilience Score?

PYC Therapeutics ASX:PYC -0.30% 36 Tariff Resilience Score is 6 as of Jul. 01, 2026. GuruFocus rates ASX:PYC with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,374 Biotechnology companies, PYC Therapeutics ranks better than 75.98% on this metric.

PYC Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

PYC Therapeutics has PYC Therapeutics has moderate tariff exposure due to its reliance on imported research materials. The biotech industry often benefits from exemptions, and the company has some flexibility in sourcing. Past tariffs have had limited impact.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes PYC Therapeutics might have Average Resilient.

PYC Therapeutics  (ASX:PYC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

PYC Therapeutics Tariff Resilience Score Related Terms

ASX:PYC vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, PYC Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PYC Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's Tariff Resilience Score falls into.


ASX:PYC
36GF Score
PYC Therapeutics Ltd ASX:PYC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
PYC Therapeutics (ASX:PYC) has a Tariff Resilience Score of 6 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, PYC Therapeutics ranks #330 out of 1374 companies in the Biotechnology industry, placing it in the top 24%.
Is PYC Therapeutics' Tariff Resilience Score too high?
PYC Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. PYC Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, PYC Therapeutics ranks #330 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PYC Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PYC Therapeutics ranks #330 out of 1374 companies for Tariff Resilience Score. This places PYC Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. PYC Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PYC Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PYC Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. PYC Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Tariff Resilience Score is 6 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
36GF Score

Get the complete analysis for ASX:PYC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.68
Price